Blood-pressure-lowering peptide (LHLWLP)
A small natural peptide that blocks ACE, the enzyme that raises blood pressure, helping keep blood pressure in check; used only as a lab research tool.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Can a tiny chemical change stop the gut from destroying this peptide before it reaches the bloodstream?
Many peptides that lower blood pressure in a lab test get chewed apart in the gut and never reach the blood. If this modification holds up, it could be a practical first step toward a food-derived blood pressure supplement that actually works when swallowed.
Which protein in the body does this peptide block, and how strongly?
Without knowing the exact target and its potency, a peptide cannot be developed into anything useful. If this hypothesis is confirmed, it gives researchers the baseline numbers they need to decide whether this compound is worth pursuing as a functional food ingredient or supplement.
Could this peptide target blood pressure without causing the dry cough that many people get from ACE inhibitor drugs?
Dry cough affects roughly 10 to 15 percent of people taking common blood pressure drugs and often leads them to stop treatment. If this peptide turns out to be selective in the way the hypothesis describes, it could point toward a gentler alternative, though this is still a very early, unproven idea.
Could this peptide work through two different pathways to lower blood pressure more effectively than through just one?
A drug combination that blocks two related enzymes simultaneously is already used in serious heart failure treatment. If a simple food-derived peptide can do something similar naturally, it could be a higher-value ingredient for cardiovascular functional foods, though confirming this would require substantial lab work.
Does the body have to digest this peptide first before it starts working?
If the gut converts LHLWLP into smaller, more potent fragments, developers could skip the parent peptide entirely and formulate the active fragment directly. That could mean a cheaper, more reliable ingredient, though it could also explain why results from lab tests sometimes do not match what happens in a living body.
Does this peptide latch onto its target at two points instead of one, making it more potent?
Inhibitors that attach to their target at two separate points tend to be more potent and harder to dislodge. If this hypothesis holds, LHLWLP would have a structural feature that could be deliberately improved upon, giving chemists a rational starting point for designing stronger food-derived blood pressure compounds.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.7822946906089783 | boltz-2 |
| ranking score | 0.8497854471206665 | boltz-2 |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 1.297 | global PDE — lower = better |
| disorder | NaN | fraction disordered |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | none |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-24 |
▸citationbibtex
@peptide{pep04884,
sequence = {LHLWLP},
target = {ace},
author = {peptidemodel},
year = {2026},
status = {computed}
}